MiNK Therapeutics (NASDAQ:INKT) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT) in a research report released on Friday morning,Benzinga reports. HC Wainwright currently has a $9.00 price target on the stock. HC Wainwright also issued estimates for MiNK Therapeutics’ FY2028 earnings at $0.24 EPS.

Separately, Robert W. Baird decreased their price target on shares of MiNK Therapeutics from $8.00 to $4.00 and set an “outperform” rating on the stock in a research note on Friday.

MiNK Therapeutics Stock Performance

INKT remained flat at $0.75 during trading hours on Friday. The company had a trading volume of 33,007 shares, compared to its average volume of 89,830. The company’s 50 day simple moving average is $0.73 and its 200-day simple moving average is $0.85. MiNK Therapeutics has a twelve month low of $0.57 and a twelve month high of $1.90. The firm has a market cap of $29.81 million, a price-to-earnings ratio of -1.93 and a beta of 0.05.

MiNK Therapeutics (NASDAQ:INKT) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.03. Analysts predict that MiNK Therapeutics will post -0.33 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC lifted its holdings in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 127,841 shares of the company’s stock after acquiring an additional 22,613 shares during the period. Renaissance Technologies LLC owned approximately 0.37% of MiNK Therapeutics worth $121,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.